United States Patent 10,874,616 (Ruxolitinib phosphate HPMC oral sustained-release): What the claims cover and how broad the patent estate is
Executive summary. US 10,874,616 is directed to oral sustained-release (SR) dosage forms of ruxolitinib phosphate that use hydroxypropyl methylcellulose (HPMC) as a sustained-release matrix former at 10% to 30% by weight, with dose strength measured as ruxolitinib free base (10 to 60 mg), and characterized by specific exposure and PK shape targets in humans (including Cmax/C12h ≤ 10 and narrower Cmax ranges and Tmax constraints in dependent claims). Claim coverage includes tablet/capsule formats, plasma concentration windows out to 8 or 12 hours, and treatment outcomes quantified over 16 weeks in terms of platelet count and hemoglobin decreases. The estate is a “formulation plus PK/PD performance” patent: infringement hinges on whether an accused product hits the stated PK ratios/ranges and, for the outcome-dependent claims, the cited hematologic endpoints under once-daily SR dosing.
What does US 10,874,616 claim about ruxolitinib oral sustained-release formulations?
Core independent claim concept (Claim 1). US 10,874,616 claims an oral SR dosage form comprising:
- Active: ruxolitinib phosphate
- Matrix former: HPMC at 10% to 30% by weight
- Dose strength: 10 to 60 mg of ruxolitinib on a free base basis
- Route: suitable for oral administration
- PK shape constraint: in humans, the ratio of mean Cmax to mean C12h is 10 or less
This creates two immediate claim boundaries:
- Compositional boundary: HPMC at 10%–30% by weight, with ruxolitinib phosphate dosed as 10–60 mg free base equivalents.
- Performance boundary: human exposure must satisfy Cmax/C12h ≤ 10 (mean values).
How broad is the HPMC “10% to 30%” matrix limitation in Claim 1?
The claim’s matrix former limitation is tight enough to exclude many alternative SR architectures:
- In scope: SR dosage forms where HPMC is the sustained-release matrix former and is present at 10% to 30% w/w.
- Potentially out of scope: products that:
- use other sustained-release polymers as the matrix former (e.g., ethylcellulose, methacrylates) as the primary SR mechanism, or
- use HPMC outside 10%–30% w/w,
- use HPMC but not as the sustained-release matrix former in the claimed sense (depending on how “matrix former” is construed in litigation).
Key strategic point. If a generic or follow-on developer uses a different SR polymer system or shifts HPMC loading outside the range, it can attack claim 1 directly on composition, without needing to litigate human PK ratios.
What PK targets constrain Claim 1 and dependent claims?
US 10,874,616 uses quantitative PK shape and exposure metrics that become central in infringement analysis.
Claim 1: Exposure shape
This is the “umbrella” PK criterion for the independent claim.
Dependent narrowing of Claim 1: Cmax
- Claim 2: Cmax ≤ 700 nM
- Claim 3: Cmax 200–700 nM
- Claim 4: Cmax 300–400 nM
Dependent narrowing: Tmax
- Claim 5: Tmax ≥ 1.5 hours
- Claim 6: Tmax 1.5–5 hours
Dependent narrowing: Cmax/C12h
- Claim 7: Cmax/C12h ≤ 4
- Claim 30: Cmax/C12h ≤ 6
- Claim 31: Cmax/C12h ≤ 5
- Claim 32: Cmax/C12h 1–10
- Claim 33: Cmax/C12h 2–7
Dependent narrowing: t1/2
Dependent narrowing: AUC0-∞
- Claim 9: AUC0-∞ 3000–4000 nM·h
- Claim 10: AUC0-∞ 3100–3800 nM·h
Dependent: plasma concentration window duration
- Claim 12: 75–500 nM for 8 hours
- Claim 13: 75–500 nM for 12 hours
Claiming style impact. Because these are mean PK metrics in humans, proving infringement typically requires:
- a product-specific bioequivalence-type study or supporting clinical PK dataset, and
- a trial court construction of how “mean” is determined (sample size, fed/fasted conditions, handling of values), plus whether the claim requires a particular study design.
How do Claims 14–21 add PD/hematologic outcome constraints?
Claims 14–21 add a pharmacodynamic performance layer over a once-daily regimen for 16 weeks.
Platelet count decrease (thrombocytopenia surrogate)
- Claim 14: mean platelet count decrease ≤ 100 × 10^9/L over 16 weeks
- Claim 15: ≤ 80 × 10^9/L
- Claim 16: ≤ 60 × 10^9/L
- Claim 17: ≤ 40 × 10^9/L
Hemoglobin decrease (anemia surrogate)
- Claim 18: mean hemoglobin decrease ≤ 15 g/L over 16 weeks
- Claim 19: ≤ 10 g/L
- Claim 20: ≤ 8 g/L
- Claim 21: ≤ 6 g/L
Legal/technical consequence. These claims are harder to satisfy (and harder to attack) without access to long-duration human outcome data for the accused dosing regimen, because infringement can become product-and-study specific. In Paragraph IV-style challenges, challengers often prefer to design products that miss the composition or core PK ratio, rather than try to argue PD outcomes.
What dosage forms are covered (tablet/capsule) and what isn’t explicitly limited?
- Claim 11: SR dosage form in the form of a tablet or capsule.
The independent claim does not specify ER coatings vs matrix tablets beyond the HPMC matrix former language. That said, the matrix former restriction plus tablet/capsule format leaves room for:
- different geometries (e.g., pellets in capsule with HPMC ER matrix),
- coatings that modulate release rate, so long as HPMC remains the sustained-release matrix former and remains at 10%–30% w/w.
Out-of-scope by omission. The claims as given do not expressly cover:
- oral solutions/suspensions,
- IM/IV routes,
- patch or implant dosage forms.
What dose strengths are explicitly claimed via free-base ruxolitinib amounts?
Claim 1 sets 10–60 mg free base equivalents. Dependent claims recite discrete strengths:
- Claim 22: 10 mg
- Claim 23: 12.5 mg
- Claim 24: 20 mg
- Claim 25: 30 mg
- Claim 26: 37.5 mg
- Claim 27: 40 mg
- Claim 28: 50 mg
- Claim 29: 60 mg
Infringement leverage. A product at a dose not in the 10–60 mg range is likely outside claim 1. Products within range but using a different SR matrix composition or PK profile can be designed around.
How does Claim 34 broaden or shift the claim boundary compared to Claim 1?
Claim 34 is an additional formulation claim with similar compositional elements but with a different or expanded half-life constraint:
- HPMC sustained-release matrix former 10%–30%
- ruxolitinib phosphate with 10–60 mg free base basis
- Cmax/C12h ≤ 10
- t1/2 3.5–11 hours (wider than Claim 8’s 4–8 hours)
Dependent claims 35 and 36 add further constraints:
- Claim 35: Cmax/C12h 2–7
- Claim 36: “reduction in thrombocytopenia or anemia relative to an immediate-release dosing regimen” (comparative clinical PD framing)
Scope implication. Claim 34 captures SR products with longer half-lives up to 11 hours, even if they do not meet the narrower 4–8 hour window in Claim 8.
What does Claim 36 require legally and technically?
Claim 36 uses a comparative PD standard:
- “reduction in thrombocytopenia or anemia relative to an immediate-release dosing regimen.”
This is typically harder for an infringement plaintiff to prove without:
- a head-to-head comparator dataset (or at least a statistically comparable immediate-release reference design),
- consistent definitions of thrombocytopenia/anemia and endpoint capture.
As a practical matter, Claim 36 functions as a backup or supplemental protection layer: if a competitor’s product matches formulation and PK but drifts on PD thresholds in 14–21, Claim 36 may still apply if the relative clinical conclusion is supported.
Which elements are the best infringement “hooks” and which are the easiest design-arounds?
Best infringement hooks (hardest to avoid)
- HPMC as sustained-release matrix former at 10%–30% w/w.
- Dose range: ruxolitinib free base 10–60 mg.
- Core PK ratio: mean Cmax/C12h ≤ 10.
These appear in the independent claim(s) and thus drive baseline infringement risk.
Easiest design-around candidates
- Change matrix former away from HPMC or shift HPMC loading outside 10%–30% w/w.
- Move PK shape by increasing Cmax relative to C12h (raising Cmax/C12h above 10).
- For secondary outcomes, miss PD thresholds:
- platelets (claims 14–17),
- hemoglobin (claims 18–21),
- or comparative relative improvements needed for Claim 36.
What “scope” does the claim language create for generic or follow-on SR products?
Given the quantitative human PK requirements, the patent is most relevant to products positioned as sustained-release ruxolitinib phosphate designed to create:
- flattened exposure curve (lower Cmax relative to 12-hour levels),
- controlled Tmax,
- and, in some dependent claims, specific exposure windows and hematologic outcomes over 16 weeks.
A generic maker attempting an SR ruxolitinib phosphate product would face risk if its clinical PK profile matches the numeric thresholds.
How to interpret claim construction pressure points (as used in infringement analysis)
-
“Sustained-release matrix former, which is hydroxypropyl methylcellulose.”
Construction likely focuses on whether HPMC is the dominant SR mechanism and in the claimed concentration window.
-
“Ratio of mean peak plasma concentration (Cmax) to mean 12-hour plasma concentration (C12h).”
The claim uses mean values and a single ratio cutoff. If an accused product has:
- mean Cmax/C12h slightly above 10, it misses Claim 1’s independent boundary even if other metrics match.
-
Measurement conditions (fasted/fed, sampling schedule, study population).
Because the claims are phrased to “administration to a human results in” these outcomes, the sampling scheme and regimen matter in evidence gathering. For litigation, claim meaning typically attaches to clinically reported mean values under the relevant regimen.
-
“Suitable for oral administration.”
This is generally not a strong differentiator. Most oral tablets/capsules will satisfy.
What is the likely patent estate structure around this single patent (practical landscape read)?
From the claim set alone, US 10,874,616 appears to function as a formulation/PK/PD claim anchor for SR ruxolitinib phosphate. In an estate, such patents are commonly supported by:
- related patents on SR compositions (same polymer class, different polymer levels),
- related patents on dosing schedules (once daily),
- related patents on PK targets (Cmax/C12h windows, Tmax windows),
- related patents on PD outcomes (platelets and hemoglobin changes),
- and sometimes composition variants (alternate salts or different SR matrix formers).
However, a complete landscape requires Orange Book listing, family members, assignees, continuation status, and prosecution history. This response is limited to the scope and claim implications contained in the text provided and therefore does not map additional family members, expiration dates, or litigation.
Key Takeaways
- US 10,874,616 is an SR formulation patent with numeric human PK performance requirements. Claim 1 is anchored on HPMC 10%–30% w/w, ruxolitinib phosphate delivering 10–60 mg free base, and mean Cmax/C12h ≤ 10.
- Dependent claims add narrow PK envelopes (Cmax bands, Tmax bands, tighter Cmax/C12h windows, t1/2 windows, and AUC ranges).
- Outcome-dependent claims (14–21 and 36) add hematologic performance over 16 weeks, which is harder to establish for infringement without long-duration clinical evidence.
- Design-around strategy is compositional or exposure-profile based. Moving away from HPMC at the claimed loading, or ensuring Cmax/C12h exceeds 10, is the most direct route to avoid Claim 1.
- Tablet/capsule format is explicitly covered, but the independent claim scope is primarily driven by composition and PK ratios rather than by a specific manufacturing process.
FAQs
1) What study metrics are most likely required to prove infringement of US 10,874,616?
Mean human Cmax, mean C12h, and derived Cmax/C12h for PK-related independent and dependent claims, plus platelet/hemoglobin endpoints over 16 weeks for the hematologic-dependent claims.
2) If a competitor matches HPMC 10%–30% but has Cmax/C12h slightly above 10, does it avoid Claim 1?
Yes for Claim 1 as written, because Claim 1 requires Cmax/C12h of 10 or less as a resulting human PK property.
3) Are the strongest claim targets for a generic likely Claim 1’s Cmax/C12h cutoff or the platelet/hemoglobin thresholds?
Claim 1’s Cmax/C12h ≤ 10 is the strongest baseline hook since it is in the independent claim; platelet/hemoglobin thresholds are narrower and dependent.
4) Does Claim 34 capture products with longer half-life than Claim 8?
Yes. Claim 34 recites t1/2 3.5–11 hours, while Claim 8 (dependent) narrows to 4–8 hours.
5) What formulation changes most directly reduce risk under this patent?
Changing the sustained-release matrix former away from HPMC or setting HPMC content outside 10%–30% w/w, and/or designing release to increase Cmax relative to C12h so Cmax/C12h > 10.
References (APA)
- United States Patent 10,874,616. “Oral sustained-release ruxolitinib phosphate dosage forms.” (Claims provided in prompt).
